Vasiliki Chounta

2.2k total citations
18 papers, 252 citations indexed

About

Vasiliki Chounta is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Vasiliki Chounta has authored 18 papers receiving a total of 252 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 13 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Vasiliki Chounta's work include HIV/AIDS Research and Interventions (17 papers), HIV Research and Treatment (13 papers) and HIV/AIDS drug development and treatment (13 papers). Vasiliki Chounta is often cited by papers focused on HIV/AIDS Research and Interventions (17 papers), HIV Research and Treatment (13 papers) and HIV/AIDS drug development and treatment (13 papers). Vasiliki Chounta collaborates with scholars based in United Kingdom, United States and Spain. Vasiliki Chounta's co-authors include Nicolas Van de Velde, William Spreen, Simon Vanveggel, Mark S. Shaefer, Krischan J Hudson, Anthony Mills, Paolo Rizzini, Fabio Maria Vecchio, Laurent Finkielsztejn and Edgar T. Overton and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Vasiliki Chounta

17 papers receiving 248 citations

Peers

Countries citing papers authored by Vasiliki Chounta

Since Specialization

Citations

This map shows the geographic impact of Vasiliki Chounta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vasiliki Chounta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vasiliki Chounta more than expected).

Fields of papers citing papers by Vasiliki Chounta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vasiliki Chounta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vasiliki Chounta. The network helps show where Vasiliki Chounta may publish in the future.

Co-authorship network of co-authors of Vasiliki Chounta

This figure shows the co-authorship network connecting the top 25 collaborators of Vasiliki Chounta. A scholar is included among the top collaborators of Vasiliki Chounta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vasiliki Chounta. Vasiliki Chounta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study 2024 ·AIDS and Behavior ·Cristina Mussini, Charles Cazanave, Eisuke Adachi, (unknown), Marta Montero, Gordon Crofoot, Vasiliki Chounta, (unknown), Kenneth Sutton, Denise Sutherland‐Phillips, (unknown), (unknown), (unknown), Patricia Rios, Ronald D’Amico, William Spreen, Jean van Wyk	3
2	Qualitative evaluation of survey questions to assess treatment preference for daily oral or long‑acting injectable antiretroviral therapy among people living with HIV 2024 ·PLoS ONE ·Cindy Garris, (unknown), Vasiliki Chounta, (unknown), Robin Dretler, Tulika Singh, Gary Sinclair	0
3	Adherence to oral antiretroviral therapy in Canada, 2010–2020 2023 ·AIDS ·Jonathan B. Angel, (unknown), Erin Arthurs, (unknown), Jean Lachaîne, Vasiliki Chounta, Marianne Harris	5
4	Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV 2023 ·Advances in Therapy ·Vasiliki Chounta, Hilary F. Byrnes, (unknown), (unknown), Christina Donatti, Jérémy Lambert	4
5	Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants 2023 ·Antimicrobial Agents and Chemotherapy ·Kelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, Herta Crauwels, (unknown), (unknown), (unknown), Vasiliki Chounta, (unknown), (unknown), Ronald D’Amico, William Spreen, Susan L. Ford	14
6	Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV 2022 ·Quality of Life Research ·Louis S. Matza, (unknown), Vasiliki Chounta, Nicolas Van de Velde	4
7	Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection 2022 ·BMC Infectious Diseases ·Vasiliki Chounta, Sonya J. Snedecor, Sterling Wu, Nicolas Van de Velde	2
8	Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries 2021 ·Sexually Transmitted Infections ·Babatunde Akinwunmi, (unknown), (unknown), (unknown), Paolo Rizzini, Fabio Maria Vecchio, (unknown), Gaëlle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta, Nicolas Van de Velde	30
9	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) 2021 ·Patient ·Vasiliki Chounta, Edgar T. Overton, Anthony Mills, Susan Swindells, (unknown), Simon Vanveggel, Rodica Van Solingen‐Ristea, Yuanyuan Wang, Krischan J Hudson, Mark S. Shaefer, David A. Margolis, Kimberly Y. Smith, William Spreen	47
10	Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study 2021 ·PLoS ONE ·Ben Parker, Tom Ward, (unknown), (unknown), Erin Arthurs, (unknown), Sarah‐Jane Anderson, Vasiliki Chounta, Nicolas Van de Velde	16
11	Effectiveness and safety of dolutegravir two‐drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta‐analysis of real‐world evidence 2021 ·HIV Medicine ·Yogesh Punekar, Daniel Parks, (unknown), (unknown), (unknown), Vasiliki Chounta, (unknown), (unknown), Shannon Ferrante, (unknown), Jean van Wyk, Annemiek de Ruiter	33
12	Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment among People Living with HIV 2020 ·Patient ·Louis S. Matza, Trena M. Paulus, Cindy Garris, Nicolas Van de Velde, Vasiliki Chounta, (unknown)	10
13	Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks 2020 ·AIDS and Behavior ·Miranda Murray, Antonio Antela, Anthony Mills, Jenny Huang, (unknown), Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, Marie-Aude Khuong-Josses, Krischan J Hudson, David Dorey, Sandy Griffith, William Spreen, Simon Vanveggel, Mark S. Shaefer, David M. Margolis, Vasiliki Chounta	53
14	Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe 2020 ·European Journal of Public Health ·Babatunde Akinwunmi, (unknown), (unknown), (unknown), Paolo Rizzini, Fabio Maria Vecchio, (unknown), Gaëlle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta, Nicolas Van de Velde	11
15	Quantifying people living with HIV who would benefit from an alternative to daily oral therapy: Perspectives from HIV physicians and people living with HIV 2020 ·SHILAP Revista de lepidopterología ·Laura Clark, Chitra Karki, (unknown), (unknown), (unknown), Paolo Rizzini, Fabio Maria Vecchio, (unknown), Gaëlle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta, Nicolas Van de Velde	8
16	1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results 2020 ·Open Forum Infectious Diseases ·Vasiliki Chounta, Enrique Bernal, Johan Lombaard, Harold Katner, Sharon Walmsley, David Dorey, William Spreen, Sandy Griffith, David M. Margolis	4
17	2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies 2019 ·Open Forum Infectious Diseases ·Alan Oglesby, (unknown), Yogesh Punekar, Vasiliki Chounta, Antonio Antela, Jessica Matthews, Lesley Kahl, Martin Gartland, Brian Wynne, Miranda Murray, (unknown)	2
18	Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia 2018 ·Value in Health Regional Issues ·Gabriel Tremblay, Vasiliki Chounta, James Piercy, Tim Holbrook, (unknown), (unknown), Yogesh Punekar	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact